Skip to content

Medical emergency? What to do

Glaxo and IAVI to develop HIV vaccine

3-RXPublished June 22, 20052 min read

Key points

  • A public-private partnership to develop a vaccine to prevent AIDS was announced on Tuesday by GlaxoSmithKline and the not-for-profit International AIDS Vaccine Initiative (IAVI).
  • The vectors are derived from adenoviruses, originally isolated from non-human primates, which have been engineered to be non-infectious and capable of efficiently delivering genes expressing HIV proteins to the immune system.
  • GSK said the research would initially focus on HIV strains circulating in Africa, although the goal was to develop vaccines for use worldwide.
  • The collaboration with IAVI would accelerate the development and was particularly important with a complicated virus like HIV with different strains in different continents.

A public-private partnership to develop a vaccine to prevent AIDS was announced on Tuesday by GlaxoSmithKline and the not-for-profit International AIDS Vaccine Initiative (IAVI).

In a statement, GSK said the collaboration -- the first between IAVI and a major vaccine company -- would facilitate early research and development of its "promising" adenovirus vaccine vector technology.

The vectors are derived from adenoviruses, originally isolated from non-human primates, which have been engineered to be non-infectious and capable of efficiently delivering genes expressing HIV proteins to the immune system.

IAVI will contribute technical expertise and funding, and GSK and IAVI researchers will form a joint R&D team.

GSK said the research would initially focus on HIV strains circulating in Africa, although the goal was to develop vaccines for use worldwide. After pre-clinical evaluation, GSK Biologicals and IAVI would conduct phase I clinical trials of the vaccine candidates.

GSK is pursuing a four-pronged approach to find an effective AIDS vaccine, said Jean Stephenne, President and General Manager of GSK Biologicals. "Our objective in the next three years is to bring these vaccine candidates into the clinic and then decide which we want to pursue in phase III later on."

The collaboration with IAVI would accelerate the development and was particularly important with a complicated virus like HIV with different strains in different continents.

Stephenne added: "The model is that for the poorest countries ... we will make (the vaccine) available at a reasonable price."

"This is a new kind of partnership that involves real scientific collaboration to accelerate the development of an AIDS vaccine," said Seth Berkley, President and CEO of the International AIDS Vaccine Initiative.

He added in a statement: "We hope this will be the beginning of a long-term partnership that brings together some of the most promising technologies in the field. We cannot think of a better partner, given GSK's long-standing commitment to addressing diseases of developing countries."

The announcement comes in the lead up to the G8 summit in Scotland in July, where world leaders are expected to build on previous commitments to expand support for research of vaccines against AIDS, as well as other developing-country diseases such as tuberculosis and malaria.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underAIDS/HIV

Keep reading

AIDS/HIV

Economic crisis could worsen HIV/AIDS epidemic: UN

Economic crisis and climate change concerns could affect the fight against the AIDS virus and lead to a "universal nightmare", the head of the United Nations' agency for HIV/AIDS said on Sunday. The global economic…

2 min read

AIDS/HIV

Possible cure for HIV patients?

On December 7th, an article was published in PLoS One that explained that researchers from UCLA AIDS Institute have found a way to use human stem cells to fight HIV-infected cells. The human stem cells can be…

1 min read

AIDS/HIV

HIV-infected Chinese children struggle with stigma

The second storey of this nondescript building in Fuyang city in China's central province of Anhui houses HIV-positive orphans, but unlike many other similar establishments, there are no signboards outside. Heavy…

4 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.